Novel Therapeutics for Fibrolamellar Carcinoma
Abstract
Our proposal focuses on a unique form of liver cancer, fibrolamellar carcinoma (FLC). This debilitating disease affects young individuals between their teenage years and mid-30's. Importantly, this cancer afflicts young men, and women in the prime of their life with none of risk factors associated with chronic liver diseases. Our multidisciplinary team of clinical and basic science investigators have put together a comprehensive experimental strategy to address 3 fundamental questions pertaining to FLC: 1) How does the DNJA-PKAc chimera initiate liver tumorigenesis? 2) What downstream signaling steps are necessary to promote FLC growth? and 3) How does FLC evade the host immune response? These questions have forged the inception of three related projects that will define new therapeutic targets at each stage of tumor development.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2021
- Accession Number
- AD1153680
Entities
People
- Venu G Pillarisetty
Organizations
- University of Washington